Phase I study of terameprocol in patients with recurrent high-grade glioma.
about
Targeting caspases in cancer therapeuticsTetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01Antiviral activity of nordihydroguaiaretic acid and its derivative tetra-O-methyl nordihydroguaiaretic acid against West Nile virus and Zika virus.DNA microstructure influences selective binding of small molecules designed to target mixed-site DNA sequencesPhase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.Creosote bush lignans for human disease treatment and prevention: Perspectives on combination therapy.Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.Recent Advances on Small-Molecule Survivin Inhibitors.Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.NDGA-P21, a novel derivative of nordihydroguaiaretic acid, inhibits glioma cell proliferation and stemness.Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma.The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells.Nordihydroguaiaretic acid activates hTRPA1 and modulates behavioral responses to noxious cold in mice.Recent advances in nanomedicine and survivin targeting in brain cancers.Inhibitors of apoptosis: clinical implications in cancer.Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.CDK4 inhibitors an emerging strategy for the treatment of melanoma
P2860
Q26821986-F6CBF882-08C5-490A-BC93-DC29C8EF99A6Q28550253-CF9F46EC-C9A5-4ED5-AABB-F9266C9B2474Q30145610-A6590661-B66D-4585-83C2-D3CD3085708CQ33554133-BAA49638-9670-477A-8F42-5BA11F8F6E1FQ35684292-DA32D563-E2F6-451D-BAE0-706B7F896D23Q35808178-80CED092-627E-4AC8-8186-F9489E1DEC86Q36871155-A64708DE-8AE9-4B04-A15E-BE721503BA2DQ37689286-E42E8474-E30F-40EB-8256-8A27903D3688Q39214188-59A74F42-EBE0-4FB2-BB2A-02B77DC6DEB0Q40201358-6CBE0625-BB5B-475F-9AA1-0D740A6C0D13Q41200870-B5E3C7D0-E4BD-4915-8C89-7E05F4DFC50FQ41539725-B2A666F7-801A-4099-9E21-591FFE45C370Q42106713-61D013E2-002C-4BF6-A8B2-26332430995BQ47378913-105E384D-A7C4-49D4-A936-174313B76D39Q47607136-CD297D6D-03BB-423F-BB99-7C48811E8581Q52981445-4A57BE13-BE1B-4E4A-B9DD-61CE38E36657Q57571832-8A150F49-9A09-4CFF-BD7B-70AB992F4B19
P2860
Phase I study of terameprocol in patients with recurrent high-grade glioma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase I study of terameprocol in patients with recurrent high-grade glioma.
@ast
Phase I study of terameprocol in patients with recurrent high-grade glioma.
@en
type
label
Phase I study of terameprocol in patients with recurrent high-grade glioma.
@ast
Phase I study of terameprocol in patients with recurrent high-grade glioma.
@en
prefLabel
Phase I study of terameprocol in patients with recurrent high-grade glioma.
@ast
Phase I study of terameprocol in patients with recurrent high-grade glioma.
@en
P2093
P2860
P356
P1433
P1476
Phase I study of terameprocol in patients with recurrent high-grade glioma.
@en
P2093
Adult Brain Tumor Consortium
David Peereboom
Jeffrey G Supko
Serena Desideri
Stuart A Grossman
Tom Mikkelsen
P2860
P304
P356
10.1093/NEUONC/NOR230
P577
2012-02-08T00:00:00Z